AiLNP

AiRNA

AiTEM

AI驱动`药物递送`和`药物发现`

AI-Driven `Drug Delivery` and `Drug Discovery`

Recently, the largest profiling of the global AI in the Drug Discovery industry made to date has been released in the form of an interactive IT-Platform and associated report by Deep Pharma Intelligence, a leading BioTech market research agency focused on sophisticated analytics, benchmarking and forecasting of emerging and frontier domains in the Pharmaceutical, BioTech and Healthcare industries.The AI in Drug Discovery platform features an interactive database of the Top 100 AI in Drug Discovery Experts, with information-rich profiles on the leading researchers, scientists, entrepreneurs and technologists committed to harnessing the potential of AI to tackle the complex challenges of drug discovery advancement.Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&amp;D, ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/bc918d11436a88cafd649d6e726d62a3.png" width="685" height="405" style="width:685px;height:405px"/></div>Dr. Chen is a member of the National Academy of Engineering, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the Controlled Release Society and a member of the Academy of Distinguished Chemical Engineers at the University of Texas at Austin. Dr. Chen holds a B.S. in Chemical Engineering from UT Austin and an M.S. and an Sc.D. in Chemical Engineering from Massachusetts Institute of Technology.Before joining METiS, Dr. Chen served as Chief Scientific Officer at Kala Pharmaceuticals, a biotech company she helped found in 2010. At Kala, she successfully translated a novel nanoparticle technology from bench to Phase III clinical trials and FDA approval, and helped to attract significant investments to the company, including an initial public offering in 2017. Prior to Kala, Dr. Chen helped start and build TransForm Pharmaceuticals, which was acquired by Johnson &amp; Johnson in 2005. She had also held various research positions at AstraZeneca and Merck.

剂泰医药联合创始人兼美国公司总裁、研发负责人陈红敏院士从全球众多创业者中脱颖而出，作为AI制药领域的企业家代表入选该100人名单。

Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&D, ranked on the list ‘TOP 100 LEADERS AI in Drug Discovery’.

剂泰医药陈红敏院士入选“全球AI药物发现专家100人”

Dr. Hongming Chen ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’

The 2023 World Artificial Intelligence Conference took place from July 6th to 8th at the Shanghai World Expo Center and the Shanghai World Expo Exhibition &amp; Convention Center. With the theme of &quot;Intelligent Connectivity Generating Future&quot;, this conference is co-sponsored by Shanghai Municipal Government, National Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Science and Technology, Cyberspace Administration of China, Chinese Academy of Sciences, Chinese Academy of Engineering, and China Association for Science and Technology. This conference is aimed at giving full play to its important role as “technology leader, application showcase, industry accelerator, and governance council”, bringing together profound wisdom, cutting-edge technologies, industrial trends, and human ecology in the global artificial intelligence field, and promoting the healthy and innovative development of artificial intelligence.On the morning of July 7th, as a representative of AI pharmaceutical companies, Dr. Chris Lai, the co-founder, and CEO of METiS Pharmaceuticals, participated upon invitation in the Financing and Investment sub-Forum of the 2023 World Artificial Intelligence Conference hosted by CICC and themed “Boundless Future, Booming of AIGC”. At the forum, he discussed the industry development and opportunities with the participants from the perspective of capital boosting the development of AI technology and shared his personal experiences and insights.<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/de922bdb70d415b9841dc474220c7a20.png"/></div>The panel discussion was chaired by Zhang Qing, Managing Director of CICC Capital. Dr. Chris Lai, the co-founder and CEO of METiS Pharmaceuticals, John Qu, Global Senior Managing Partner of McKinsey &amp; Company, Han Wei, Chairman of AIForceTech, Ren Peng, Vice President at Perfect World and Head of Strategic Investment Department of, Nyx He, Senior Vice President and Partner at BrainCo, Wang Xiao, Partner at Unity Venture, and Zhang Suyang, Partner at Volcanics Venture, conducted a fruitful collision of ideas around the topic of“AI investment in the primary market at the dawn of a new wave”, actively offered advice and suggestions, and contributed their respective experiences and insights.<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/9c62b8356adaf241e7897d474d3a758c.png"/></div>Dr. Lai introduced the key role of capital in the early development of AI companies, drawing on his experience as the founder of an AI-driven drug delivery and drug R&amp;D company. METiS Pharmaceuticals was founded by a group of MIT scientists and a member of the National Academy of Engineering (USA) in 2020. The founding of the company coincided with the outbreak of the COVID-19 pandemic, so all R&amp;D plans were put on hold. As a result, the founding team resolutely moved the core team from the United States to China, as well as their developing work of the platforms. Fortunately, METIS received adequate support from the Hangzhou Municipal Government in terms of start-up funds and laboratory placement, and therefore, quickly settled down in Hangzhou, China. Subsequently, the experimental data was quickly recognized by the capital market. For example, the delivery and transfection efficiency of nanocarriers designed by METiS is more than ten times higher than that of the industry giant Moderna. Meanwhile, METiS has addressed the delivery problems of the lungs, brain, tumors, immune organs, and muscles that are difficult for the industry to overcome. These impressive achievements obtained the support of leading funds, including Sequoia China, 5Y Capital, PICC Capital, and Lightspeed China. Thanks to the support of capital, METiS Pharmaceuticals has grown rapidly in the past three years and is now an innovative biotechnology company that has begun to take shape and focuses on AI-driven drug delivery and drug discovery.<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/d4ea59defb2e554d181c1428fb4109b9.png"/></div>Dr. Lai is also very optimistic about the future of artificial intelligence technology. In recent years, he has witnessed the &quot;third drug revolution&quot; – the gene therapy drugs based on nucleic acid DNA and RNA codes, following the small molecule targeted drugs and antibody drugs. The mRNA vaccines developed by Moderna and BioNTech performed outstandingly during the COVID-19 pandemic, bringing nucleic acid gene drugs to the masses. The nano-delivery carrier LNP and RNA sequence have proved to be safer than expected, with unexpected drug effects, which has brought a wave of technological and financial benefits to the biopharmaceutical industry. METiS Pharmaceuticals has also joined the wave and quickly deployed the AI-driven nucleic acid delivery system design platform (AiLNP). Thanks to the contributions of the top scientists from MIT, AI technology platforms, and the capital market, METiS has created drug delivery and development capabilities that surpass the industry.Since the decoding of the human genome in 2000, the academic community has accumulated a large number of breakthroughs in molecular biology and genetic coding. These breakthroughs have led to significant progress in the development of nucleic acid-based gene drugs. The next 3-5 years will be a critical moment for the CGT industry, and the key technology to overcome the challenges is drug delivery. Those who will make huge technological breakthroughs and seize the market opportunities will be those who can make nano-delivery carriers that can accurately target and efficiently deliver nucleic acid drugs to disease tissues, and those who can cooperate deeply with major pharmaceutical multinationals.In addition, Dr. Lai looks forward to active support from the supervision authorities for the clinical development of such innovative drugs. He believes that with the efforts of pharmaceutical companies and the investment of capital, China will become a leader in the “third drug revolution” and build a gene drug ecosystem that will promote the R&amp;D of more innovative drugs and bring more good drugs to patients.

从资本助推AI技术发展的角度，和与会者共同探讨了行业发展和机遇，并分享个人经验和见解。

Discussing the industry development and opportunities with the participants from the perspective of capital boosting the development of AI technology and shared his personal experiences and i

剂泰医药赖才达博士出席2023世界人工智能大会投融资主题论坛

METiS Pharmaceuticals CEO Dr. Chris Lai Attends the 2023 World Artificial Intelligence Conference Financing and Investment Sub-Forum

剂泰医药此次入选杭州市企业高新技术研究开发中心，证明企业在技术研发、创新能力、设备先进水平、对科技投入的重视度、人才配备及组织架构等多方面，都已达到了官方的认定标准。

剂泰医药获“2023年杭州市企业高新技术研究开发中心”认定

在2022年度的资本大环境下，获此殊荣，这充分体现了医药领域与资本市场对于剂泰医药自主创新能力和广阔发展前景的认可。

剂泰医药荣获2022年度“中国医疗及健康服务产业最佳生物医药领域投资案例 TOP10”

剂泰医药（METiS）是全球首家以人工智能驱动药物递送和药物发现的生物技术公司，集合人工智能、机器学习和量子模拟等先进技术，旨在实现更有效的创新递送材料设计、候选药物选择和制剂设计、“可编程核酸药物”开发与核酸递送设计。

核心技术

业务|Business

管线|Pipeline

剂泰医药陈红敏院士入选“全球AI药物发现专家100人”

剂泰医药赖才达博士出席2023世界人工智能大会投融资主题论坛

剂泰医药获“2023年杭州市企业高新技术研究开发中心”认定

剂泰医药荣获2022年度“中国医疗及健康服务产业最佳生物医药领域投资案例 TOP10”